Effect of thermal helium-oxygen mixture on viral load in COVID-19
L. V. Shogenova,
S. D. Varfolomeev,
V. I. Bykov,
S. B. Tsybenova,
A. M. Ryabokon,
S. V. Zhuravel,
I. I. Utkina,
P. V. Gavrilov,
S. S. Petrikov,
A. G. Chuchalin,
A. A. Panin https://doi.org/10.18093/0869-0189-2020-30-5-533-543
Abstract
In this paper, we will discuss the use of t-Не/О2 in the treatment of patients with the viral disease COVID-19. The aim of the study is to evaluate the effect of thermal helium-oxygen therapy on viral load, inflammatory markers, and antibody synthesis. Methods. A single-center, randomized, prospective study included 60 patients with COVID-19. Patients were divided into two groups: 1 (n = 30; 17 male, 13 female) – t-Не/О2 therapy was included in the standard COVID-19 treatment Protocol; 2 (n = 30; 16 male, 14 female) – standard therapy in accordance with the clinical recommendations of Healthcare Ministry of Russia for patients with COVID-19. Of the 60 patients included in the study, 28 (46.7%) were medical professionals. The median age of patients in the study was 56.7 (45 – 61) years old. In the group 1 – 58 (45 – 59.5) years old, in the group 2 – 55 (46 – 66) years old. All patients had a positive test of SARS-CoV-2 coronavirus RNA, CT signs of “ground-glass opacity” type lung damage, and areas of air space consolidation. Patients were comparable by gender, age, body mass index (BMI), area of lesion of the pulmonary parenchyma, laboratory data. Results. As a result of the use of t-Не/О2, the elimination of the SARS-CoV-2 virus occurred within 48 – 72 hours from the start of inhalation and was confirmed by PCR test. The following changes were found in all patients: synthesis of IgM and IgG antibodies, increase in lymphocytes level, decrease of C-reactive protein, restoration of alanine aminotransferase and aspartate aminotransferase levels, D-dimer, and ferritin. These signs became more pronounced in the 1st group within 72 – 168 hours, compared with the 2nd group, where these results were achieved on the 10th day of therapy. Conclusion. Тhe inclusion of thermal inhalation a gas mixture of helium and oxygen (t-Не/О2) in the standard therapy of patients carrying infectious disease caused by SARS-CоV-2 with CT signs of COVID-19 pneumonia (СT1, CT2 grades) reduces the viral load by stimulating antibody synthesis, as the type of immunoglobulin G, and immunoglobulin M causing the effect of “termovaccination”; increases the effectiveness of treatment, reducing the markers of inflammation.
About the Authors
L. V. Shogenova
N.I.Pirogov Federal Russian National Research Medical University, Healthcare Ministry of Russia; D.D.Pletnev City Teaching Hospital, Moscow Healthcare Department
Russian Federation
Russian Federation
Lyudmila V. Shogenova – Сandidate of Medicine, Associate Professor, Department of Hospital Therapy, Pediatric Faculty, N.I.Pirogov Federal Russian National Research Medical University, Healthcare Ministry of Russia; Аnesthesiologist-resuscitator, D.D.Pletnev City Teaching Hospital, Moscow Healthcare Department. SPIN: 6210-7482
ul. Ostrovityanova 1, Moscow, 117997
ul. Odinnadtsataya Parkovaya 32, Moscow, 105077
tel.: (926) 215-37-06
S. D. Varfolomeev
Institute of physical and chemical bases of functioning of networks of neurons and artificial intelligence, M.V.Lomonosov Moscow Federal State University; N.M.Emanuel’ Federal State Institute of Biochemical Physics, Russian Academy of Sciences; M.V.Lomonosov Moscow Federal State University
Russian Federation
Russian Federation
Sergey D. Varfolomeev – Doctor of Сhemistry, Professor, Corresponding Member of Russian Academy of Sciences, Scientific Аdviser, N.M.Emanuel’ Federal State Institute of Biochemical Physics, Russian Academy of Sciences, Head of the Department of Chemical Enzymology, Chemistry Faculty, M.V.Lomonosov Moscow Federal State University. SPIN: 7873-3673
Lomonosovsky Prospekt 27, build. 1, offices E801–E804, A818, 119192, Moscow
Kosygina ul. 4, Moscow, 119991
Leninskie gory 1, Moscow, 119991
tel.: (903) 260-01-21
V. I. Bykov
N.M.Emanuel’ Federal State Institute of Biochemical Physics, Russian Academy of Sciences
Russian Federation
Russian Federation
Valeriy I. Bykov – Doctor of Physics & Mathematics, Professor, Chief Researcher. Author ID: 55425483000
Kosygina ul. 4, Moscow, 119991
tel.: (499) 135-78-94
S. B. Tsybenova
N.M.Emanuel’ Federal State Institute of Biochemical Physics, Russian Academy of Sciences
Russian Federation
Russian Federation
Svetlana B. Tsybenova – Doctor of Physics & Mathematics, Аssociate Professor, Leading researcher, Laboratory of functional properties of biopolymers
Kosygina ul. 4, Moscow, 119991
tel.: (915) 304-93-87
A. M. Ryabokon
N.M.Emanuel’ Federal State Institute of Biochemical Physics, Russian Academy of Sciences; M.V.Lomonosov Moscow Federal State University
Russian Federation
Russian Federation
Anna M. Ryabokon’ – Candidate of Сhemistry, Senior scientist, N.M.Emanuel’ Federal State Institute of Biochemical Physics, Russian Academy of Sciences, Researcher, Department of Chemical Enzymology, Chemistry Faculty, M.V.Lomonosov Moscow Federal State University. SPIN: 7322-5643
Kosygina ul. 4, Moscow, 119991
Leninskie gory 1, Moscow, 119991
tel.: (916) 542-10-93
S. V. Zhuravel
N.V.Sklifosovskiy State Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
Russian Federation
Sergey V. Zhuravel – Doctor of Medicine, Head оf Scientific Department оf Anaesthesiology And Intensive Care Unit. SPIN: 5338-0571
Bol. Sukharevskaya pl. 3, Moscow, 129090
tel.: (903) 618-32-91
I. I. Utkina
N.V.Sklifosovskiy State Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
Russian Federation
Irina I. Utkina – Сandidate of Medicine, Senior scientist, Scientific Department оf Anaesthesiology And Intensive Care Unit. SPIN: 8105-7338
Bol. Sukharevskaya pl. 3, Moscow, 129090
tel.: (909) 930-13-01
P. V. Gavrilov
N.V.Sklifosovskiy State Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
Russian Federation
Pavel V. Gavrilov – Researcher, Scientific Department оf Anaesthesiology And Intensive Care Unit. SPIN: 8290-5602
Bol. Sukharevskaya pl. 3, Moscow, 129090
tel.: (977) 965-78-00
S. S. Petrikov
N.V.Sklifosovskiy State Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
Russian Federation
Sergey S. Petrikov – Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Director
Bol. Sukharevskaya pl. 3, Moscow, 129090
tel.: (903) 736-86-69
A. G. Chuchalin
N.I.Pirogov Federal Russian National Research Medical University, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Aleksandr G. Chuchalin – Doctor of Medicine, Professor, Academician of Russian Academy of Sciences, Head of Department of Hospital Internal Medicine, Pediatric Faculty, Chairman of the Executive Board of Russian Respiratory Society. SPIN: 7742-2054
ul. Ostrovityanova 1, Moscow, 117997
tel.: (499) 780-08-50
A. A. Panin
“Medtekhinnovatsii” Limited Liability Company
Russian Federation
Russian Federation
Aleksandr A. Panin – Doctor of Economics, General Director
Blagoveshchenskiy per. 3, build. 1, Moscow, 123001
tel.: (499) 691-99-32
References
1. World Health Organization. Novel Coronavirus – China. Available at: https://www.who.int/csr/don/12-january-2020novel-coronavirus-china/en/ [Accessed: April 20, 2020].
2. Zhou P., Yang X.L., Wang X.G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579 (7798): 270–273. DOI: 10.1038/s41586-020-2012-7.
3. McGonagle D., Sharif K., O’Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 2020; 19 (6): 102537. DOI: 10.1016/j.autrev.2020.102537.
4. Rabaan A.A., Al-Ahmed S.H., Haque S. et al. SARSCoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez. Med. 2020; 28 (2) 174–184.
5. Scavone C., Brusco S., Bertini M. et al. Current pharmacological treatments forCOVID-19: What’s next? Br. J. Pharmacol. 2020: 10.1111/bph.15072. [Preprint. Posted 2020, Apr. 24]. DOI: 10.1111/bph.15072.
6. Ye M., Fu D., Ren Y. et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J. Med. Virol. 2020; 92 (10): 10.1002/jmv.25882. DOI: 10.1002/jmv.25882.
7. Kalil A.C. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020; 323 (19): 1897–1898. DOI: 10.1001/jama.2020.4742.
8. Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229) 1033–1034. DOI: 10.1016/S01406736(20)30628-0.
9. Kapitza P. The liquefaction of helium by an adiabatic method without precooling with liquid hydrogen. Nature. 1934; 133 (3367): 708.
10. Kapitza P. The liquefaction of helium by an adiabatic method. Proc. Roy. Soc. (Lond.). 1934; A147 (860): 189–211.
11. Kapitsa P.L. The viscosity of liquid helium at temperatures below the λ point. Reports of the USSR Academy of Sciences. Doklady Akademii nauk SSSR. 1938; 18 (1): 21–23 (in Russian).
12. Kapitsa P.L. Superfluidity of liquid helium-II. Advances in physical sciences. Uspekhi fizicheskikh nauk. 1944; 26 (2): 133–143. DOI: 10.3367/UFNr.0026.194402b.0133 (in Russian).
13. Livanova A.M. [Landau]. 2 nd Edn. Moscow: Znanie; 1983.
14. Kim T., Chuchalin A., Martynov M. et al. Efficacy and safety of thermic helium-oxygen (t-He/O ) mixture in reducing hypoxemia in acute ischemic stroke2 patients. Eur. Respir. J. 2019; 54 (Suppl. 63): PA2284. DOI: 10.1183/13993003.congress-2019.PA2284.
15. Chuchalin A.G., Gusev U.I., Martynov M.Yu. et al. Pulmonary insufficiency in acute stroke: risk factors and mechanisms of development. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2020; 120 (7–1): 7–16. DOI: 10.17116/jnevro20201200717 (in Russian).
16. Varfolomeev S.D., Panin A.A., Bykov V.I. et al. Kinetic model of development of acute viral infection in the human body. Critical conditions, control mechanisms, “thermoheliox. Izvestiya RAN. 2020; 6: 1179–1184 (in Russian).
17. Varfolomeev S.D., Panin A.A., Ryabokon’ A.M. et al. Thermal heliox proteome. High-temperature heliox does not cause destruction of human respiratory system cells. Terapevticheskiy arkhiv. 2020; 92 (6): 69–72 (in Russian).
18. Healthministry of the Russian Federation. Coronavirus symptoms, signs, general information, answers to questions. Available at: https://www.rosminzdrav.ru/ministry/covid19 (in Russian).
Review
For citations:
Shogenova L.V., Varfolomeev S.D., Bykov V.I., Tsybenova S.B., Ryabokon A.M., Zhuravel S.V., Utkina I.I., Gavrilov P.V., Petrikov S.S., Chuchalin A.G., Panin A.A. Effect of thermal helium-oxygen mixture on viral load in COVID-19. PULMONOLOGIYA. 2020;30(5):533-543. https://doi.org/10.18093/0869-0189-2020-30-5-533-543
Views:
1973
Email this article 